Research & Development

IQVIA to acquire Charles River drug discovery assets

IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities.

Novo Nordisk and Vivtex collaborate for oral medicines development

Novo Nordisk and Vivtex have entered a partnership focused on developing next-generation oral biologic therapies to treat obesity, diabetes and related comorbidities.

Slate Medicines raises $130m in funds to progress anti-PACAP treatments

Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.

FDA accepts Beren Therapeutics’ NDA for Niemann-Pick disease

Beren Therapeutics has received the US Food and Drug Administration (FDA) acceptance to review its New Drug Application (NDA) for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset Niemann-Pick disease type C (NPC).

AbbVie announces $380m investment in North Chicago API facilities

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago site in Illinois, US.

Roche receives FDA acceptance for giredestrant combo NDA

Roche has obtained acceptance from the US Food and Drug Administration (FDA) for its new drug application (NDA) submitted for giredestrant, an oral therapy, along with everolimus to treat breast cancer.

Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research

Boehringer Ingelheim India has signed a memorandum of understanding (MoU) to enhance pharmaceutical education and research collaboration.

Syngene and VivaMed collaborate on therapeutic programmes

Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI-derived repurposed therapeutic programmes.

Novartis enters licensing agreement with UNP for peptide therapeutics

Novartis has signed a research partnership and licensing agreement with Unnatural Products (UNP) valued at up to $1.7bn to develop macrocyclic peptide therapeutics targeting cardiovascular diseases.